

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-34 (canceled).

Claim 35 (currently amended): An isolated virus (~~RRV~~) as deposited with ATCC as deposit accession number VR-2601.

Claim 36 (currently amended): A purified virus, having comprising a nucleic acid molecule, wherein the nucleic acid molecule comprises a sequence

- (a) shown in SEQ ID NO:1 or
- (b) ~~a conservative variant thereof at least 95% identical to the nucleic acid sequence shown in SEQ ID NO:1, wherein inoculation of an immunocompromised non-human primate with a viral particle comprising the nucleic acid molecule results in lymphadenopathy in the non-human primate.~~

Claims 37-46 (canceled).

Claim 47 (currently amended): [A] An experimentally housed non-human mammal purposefully infected with the purified virus of claim 36.

Claim 48 (currently amended): The experimentally housed mammal of claim 47, wherein the mammal is a non-human primate.

Claims 49-51 (canceled).

Claim 52 (currently amended): An isolated nucleic acid molecule encoding all proteins encoded by the virus of claim 36, wherein inoculation of an immunocompromised non-human

primate with a viral particle comprising the nucleic acid molecule results in lymphadenopathy in the non-human primate and having a biological activity of an RRV virus.

Claims 53-58 (canceled).

Claim 59 (currently amended): A method for producing a non-human primate model for testing potential treatments for a condition associated an infection with the virus of claim 36, comprising

- (a) administering a treatment to the primate to render the primate immunocompromised; and
- (b) infecting the primate with the purified virus of claim 36.

Claim 60 (previously presented): The method of claim 59, wherein the condition is Kaposi's sarcoma ~~and lymphoproliferative disorders or a lymphoproliferative disorder.~~

Claim 61 (previously presented): The method of claim 59, wherein the treatment used to render the primate immunocompromised is infection with SIV.

Claim 62 (previously presented): The method of claim 59, wherein the non-human primate is a Rhesus macaque monkey.

Claims 63-68 (canceled).

Claim 69 (new): The purified virus of claim 36, comprising a nucleic acid sequence set forth as SEQ ID NO: 1.

Claim 70 (new): The purified virus of claim 36, comprising a nucleic acid sequence at least 95% identical to SEQ ID NO: 1.

Claim 71 (new): The purified virus of claim 36, comprising a nucleic acid sequence at least 98% identical to SEQ ID NO: 1.